Biogen's Litifilimab Shows Significant Efficacy in Cutaneous Lupus Erythematosus Trial

Biogen has announced positive results from the Phase 2 part of the AMETHYST trial for litifilimab in cutaneous lupus erythematosus (CLE). The drug met the primary endpoint of reducing disease activity in CLE patients at Week 16, with more litifilimab participants achieving clear/almost clear skin. This is the second positive Phase 2 trial for litifilimab, which has the potential to become the first approved targeted therapy for CLE.